• Gilead Sciences (NasdaqGS:GILD) completed its acquisition of Tubulis, adding next generation antibody drug conjugate technologies to its oncology portfolio.
• The company received first in class FDA approval for Hepcludex to treat chronic hepatitis delta virus infection.
• Trodelvy received a positive European regulatory recommendation in advanced breast cancer.
• Gilead renewed its multi year collaboration with the World Health Organization to combat visceral leishmaniasis.

For investors tracking Gilead Sciences at a share price of $134.36, these updates sit on top of a share move of 3.7% over the past week and 10.5% year to date. Returns of 28.5% over 1 year and 144.9% over 5 years indicate that the stock has already rewarded long term holders, while the value score of 4 may interest readers focused on fundamentals.

With oncology, viral hepatitis and global health partnerships all moving at once, Gilead is reshaping how its future pipeline and reputation could look. Readers may want to watch how execution around Tubulis integration, Hepcludex uptake, Trodelvy in Europe and the expanded WHO work translates into future updates on revenue mix, R&D priorities and regional exposure.

Stay updated on the most important news stories for Gilead Sciences by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Gilead Sciences.

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$134.36, the stock trades about 15% below the US$157.83 analyst consensus target.
• ✅ Simply Wall St Valuation: Simply Wall St flags the shares as trading around 50% below its estimated fair value.
• ✅ Recent Momentum: The stock is up 3.0% over the last 30 days.

There is only one way to know the right time to buy, sell or hold Gilead Sciences. Head to Simply Wall St's company report for the latest analysis of Gilead Sciences's Fair Value.

Key Considerations

• 📊 Tubulis, Hepcludex and Trodelvy together widen Gilead's oncology and virology reach, which could influence how concentrated its revenue mix is over time.
• 📊 Watch adoption of Hepcludex in hepatitis delta, European uptake of Trodelvy and any disclosed milestones from the WHO partnership as indicators of traction.
• ⚠️ Simply Wall St highlights a high level of debt as a minor risk, so investors may want to see how new investments are balanced against the balance sheet.

Dig Deeper

For the full picture, including more risks and rewards, check out the complete Gilead Sciences analysis. Alternatively, you can visit the community page for Gilead Sciences to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.